USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 15, 2022 | Jun 2022 | $-0.28 | - | $-0.04 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 15, 2022 | Jun 2022 | $22.14M | - | $17.84M |
Fortress Biotech's next earnings date is Monday, Aug 15, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Jun 2022 | 3 | $-0.28 | $-0.38 | $-0.19 |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 4 | $-0.93 | $-1.50 | $-0.70 |
Dec 2023 | 4 | $-0.43 | $-1.45 | $1.30 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Jun 2022 | 1 / 0 | $-0.11 | $-0.02 | $-0.02 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 1 / 0 | $-0.39 | $-0.02 | $-0.02 |
Dec 2023 | 0 / 0 | $0.18 | $0.72 | $0.72 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|---|---|---|---|
Jun 2022 | 4 | $22.14M | $19.30M | $24.97M |
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 5 | $96.11M | $84.20M | $103.20M |
Dec 2023 | 4 | $125.77M | $102.90M | $169.80M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
May 16, 2022 | Mar 2022 | $-0.28 | - | - |
Mar 23, 2022 | Dec 2021 | $0.18 | $-0.38 | -311.11% |
Nov 15, 2021 | Sep 2021 | $-0.11 | $-0.26 | -136.36% |
Aug 16, 2021 | Jun 2021 | $-0.17 | $-0.04 | 76.19% |
May 16, 2021 | Mar 2021 | $-0.15 | $-0.11 | 25.42% |
Mar 31, 2021 | Dec 2020 | $-0.14 | $-0.06 | 55.88% |
Nov 9, 2020 | Sep 2020 | $-0.18 | $-0.20 | -11.11% |
Aug 10, 2020 | Jun 2020 | $-0.23 | $-0.19 | 15.56% |
May 11, 2020 | Mar 2020 | $-0.24 | $-0.19 | 20.83% |
Mar 16, 2020 | Dec 2019 | $-0.28 | $-0.27 | 2.70% |
Nov 12, 2019 | Sep 2019 | $-0.30 | $-0.22 | 26.67% |
Aug 9, 2019 | Jun 2019 | $-0.46 | $-0.24 | 47.83% |
May 10, 2019 | Mar 2019 | $-0.58 | $0.02 | 103.45% |
Mar 18, 2019 | Dec 2018 | $-0.58 | $-0.58 | - |
Nov 9, 2018 | Sep 2018 | $-0.57 | $-0.37 | 35.09% |
Aug 9, 2018 | Jun 2018 | $-0.59 | $-0.50 | 14.78% |
May 10, 2018 | Mar 2018 | $-0.40 | $-0.49 | -22.50% |
Mar 16, 2018 | Dec 2017 | $-0.63 | $-0.21 | 66.40% |
Nov 9, 2017 | Sep 2017 | $-0.43 | $-0.67 | -57.65% |
Aug 9, 2017 | Jun 2017 | $-0.30 | $-0.43 | -45.76% |
May 10, 2017 | Mar 2017 | $-0.36 | $-0.30 | 16.67% |
Mar 16, 2017 | Dec 2016 | $-0.31 | $-0.44 | -41.94% |
Nov 9, 2016 | Sep 2016 | $-0.20 | $-0.32 | -60.00% |
Aug 9, 2016 | Jun 2016 | $-0.29 | $-0.31 | -6.90% |
May 10, 2016 | Mar 2016 | - | $-0.31 | - |
Mar 15, 2016 | Dec 2015 | $-0.09 | $-0.30 | -227.78% |
Nov 9, 2015 | Sep 2015 | $-0.13 | $-0.46 | -253.85% |
Aug 10, 2015 | Jun 2015 | $-0.14 | $-0.16 | -14.29% |
May 11, 2015 | Mar 2015 | $-0.11 | $-0.31 | -181.82% |
Mar 16, 2015 | Dec 2014 | - | $-0.10 | - |
Nov 6, 2014 | Sep 2014 | - | $-0.13 | - |
Aug 11, 2014 | Jun 2014 | $-0.18 | $-0.13 | 27.78% |
May 12, 2014 | Mar 2014 | $-0.20 | $-0.21 | -5.00% |
Mar 14, 2014 | Dec 2013 | $-0.22 | $-0.27 | -22.73% |
Nov 1, 2013 | Sep 2013 | $-0.31 | $-0.24 | 22.58% |
Aug 5, 2013 | Jun 2013 | $-0.34 | $-0.38 | -11.76% |
May 8, 2013 | Mar 2013 | $-0.30 | $-0.35 | -16.67% |
Mar 14, 2013 | Dec 2012 | $-0.28 | $-0.32 | -14.29% |
Nov 14, 2012 | Sep 2012 | $-0.28 | $-0.24 | 14.29% |
Aug 8, 2012 | Jun 2012 | $-0.40 | $-0.34 | 15.00% |
May 15, 2012 | Mar 2012 | $-0.31 | $-0.35 | -12.90% |
Mar 29, 2012 | Dec 2011 | $-0.32 | $-0.52 | -62.50% |
Nov 30, 2011 | Sep 2011 | - | $-0.48 | - |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 23, 2022 | Dec 2021 | $-0.26 | $-0.79 | - |
Mar 31, 2021 | Dec 2020 | $-0.73 | $-0.64 | - |
Mar 16, 2020 | Dec 2019 | $-0.72 | $-0.71 | - |
Mar 18, 2019 | Dec 2018 | $-1.96 | $-1.94 | - |
Mar 16, 2018 | Dec 2017 | $-2.04 | $-1.61 | - |
Mar 16, 2017 | Dec 2016 | - | $-1.38 | - |
Mar 15, 2016 | Dec 2015 | - | $-1.23 | - |
Mar 16, 2015 | Dec 2014 | - | $-0.57 | - |
Mar 14, 2014 | Dec 2013 | - | $-1.24 | - |
Mar 14, 2013 | Dec 2012 | - | $-1.25 | - |
Mar 29, 2012 | Dec 2011 | - | $-1.00 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
May 16, 2022 | Mar 2022 | $20.67M | - | - |
Mar 23, 2022 | Dec 2021 | $48.32M | $12.62M | 0.26% |
Nov 15, 2021 | Sep 2021 | $18.42M | $21.09M | 1.14% |
Aug 16, 2021 | Jun 2021 | $17.84M | $17.84M | 1.00% |
May 16, 2021 | Mar 2021 | $13.41M | $11.59M | 0.86% |
Mar 31, 2021 | Dec 2020 | $12.16M | $13.75M | 1.13% |
Nov 9, 2020 | Sep 2020 | $11.32M | $9.47M | 0.84% |
Aug 10, 2020 | Jun 2020 | $11.03M | $9.46M | 0.86% |
May 11, 2020 | Mar 2020 | $11.29M | $12.92M | 1.14% |
Mar 16, 2020 | Dec 2019 | $11.46M | $11.13M | 0.97% |
Nov 12, 2019 | Sep 2019 | $8.23M | $9.77M | 1.19% |
Aug 9, 2019 | Jun 2019 | $7.51M | $9.25M | 1.23% |
May 10, 2019 | Mar 2019 | $6.41M | $6.48M | 1.01% |
Mar 18, 2019 | Dec 2018 | $63.29M | $-156.07M | - |
Nov 9, 2018 | Sep 2018 | $64.88M | $63.69M | 0.98% |
Aug 9, 2018 | Jun 2018 | $48.93M | $63.83M | 1.30% |
May 10, 2018 | Mar 2018 | $27.15M | $55.42M | 2.04% |
Mar 16, 2018 | Dec 2017 | $48.03M | $45.32M | 0.94% |
Nov 9, 2017 | Sep 2017 | $50.75M | $46.89M | 0.92% |
Aug 9, 2017 | Jun 2017 | $44.10M | $50.70M | 1.15% |
May 10, 2017 | Mar 2017 | - | $44.68M | - |
Mar 16, 2017 | Dec 2016 | - | $12.62M | - |
Nov 9, 2016 | Sep 2016 | - | $975.00K | - |
Aug 9, 2016 | Jun 2016 | - | $2.23M | - |
May 10, 2016 | Mar 2016 | - | $660.00K | - |
Mar 15, 2016 | Dec 2015 | - | $338.00K | - |
Nov 9, 2015 | Sep 2015 | - | $25.00K | - |
Aug 10, 2015 | Jun 2015 | - | $500.00K | - |
May 11, 2015 | Mar 2015 | - | $500.00K | - |
Mar 16, 2015 | Dec 2014 | - | $0.00 | - |
Nov 6, 2014 | Sep 2014 | - | $0.00 | - |
Aug 11, 2014 | Jun 2014 | - | $0.00 | - |
May 12, 2014 | Mar 2014 | - | $0.00 | - |
Mar 14, 2014 | Dec 2013 | - | $0.00 | - |
Nov 1, 2013 | Sep 2013 | - | $0.00 | - |
Aug 5, 2013 | Jun 2013 | - | $0.00 | - |
May 8, 2013 | Mar 2013 | - | $0.00 | - |
Mar 14, 2013 | Dec 2012 | - | $0.00 | - |
Nov 14, 2012 | Sep 2012 | - | $0.00 | - |
Aug 8, 2012 | Jun 2012 | - | $0.00 | - |
May 15, 2012 | Mar 2012 | - | $0.00 | - |
Mar 29, 2012 | Dec 2011 | - | $0.00 | - |
Nov 30, 2011 | Sep 2011 | - | $0.00 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 23, 2022 | Dec 2021 | $98.82M | $63.13M | -36.11% |
Mar 31, 2021 | Dec 2020 | $44.02M | $45.60M | 3.59% |
Mar 16, 2020 | Dec 2019 | $36.96M | $36.63M | -0.90% |
Mar 18, 2019 | Dec 2018 | $246.20M | $26.88M | -89.08% |
Mar 16, 2018 | Dec 2017 | $189.60M | $187.58M | -1.06% |
Mar 16, 2017 | Dec 2016 | - | $16.48M | - |
Mar 15, 2016 | Dec 2015 | - | $863.00K | - |
Mar 16, 2015 | Dec 2014 | - | $0.00 | - |
Mar 14, 2014 | Dec 2013 | - | $0.00 | - |
Mar 14, 2013 | Dec 2012 | - | $0.00 | - |
Mar 29, 2012 | Dec 2011 | - | $0.00 | - |
FBIO's next earnings date is Monday, Aug 15, 2022 for the fiscal quarter ending Jun 30, 2022.
According to analysts, the average EPS estimation for Fortress Biotech's next quarterly earnings is $-0.28, with a low EPS estimation of $-0.38, and a high estimation of $-0.19.
Over the last 1 month, EPS estimates have seen 1 upward revisions and 0 downward. The EPS 1 month trend is $-0.11, the last 2 month trend is $-0.02, and the 3 month trend is $-0.02.
Based on analysts, the average revenue estimation is $22.14M, with a low revenue estimation of $19.30M, and a high estimation of $24.97M.
Fortress Biotech's previous earnings date was May 16, 2022 for its fiscal quarter ended Mar 31, 2022.
Fortress Biotech's previous annual earnings date was Mar 23, 2022 for its fiscal year ended Dec 31, 2021.
FBIO's earnings per share (EPS) was $-0.79, missing the consensus analysts forecast of $-0.26 by 203.85% , and lower than the previous year's EPS (Dec 2020) by 23.44%.
Revenues were $63.13M, worse than the forecast of $98.82M by -36.11%, and up by 38.45% from previous year's revenue.
The company reported a net income of $-64.70M.
Fortress Biotech reported a free cash flow of $-121.11M for its fiscal year, compared to $-90.85M a year ago.
The company ended the fiscal year with $109.78M in total debt, an increase of 65.86% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.